(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 31.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.74%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Ardelyx's revenue in 2026 is $427,679,000.On average, 13 Wall Street analysts forecast ARDX's revenue for 2026 to be $137,044,493,026, with the lowest ARDX revenue forecast at $127,096,619,612, and the highest ARDX revenue forecast at $148,289,270,722. On average, 13 Wall Street analysts forecast ARDX's revenue for 2027 to be $184,973,134,692, with the lowest ARDX revenue forecast at $168,908,813,655, and the highest ARDX revenue forecast at $201,020,163,671.
In 2028, ARDX is forecast to generate $245,655,903,608 in revenue, with the lowest revenue forecast at $214,725,354,062 and the highest revenue forecast at $282,848,648,115.